{
    "zip": "10016",
    "sector": "Healthcare",
    "fullTimeEmployees": 30,
    "longBusinessSummary": "Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.",
    "city": "New York",
    "phone": "646-767-3870",
    "state": "NY",
    "country": "United States",
    "companyOfficers": [],
    "website": "http://www.actiniumpharma.com",
    "maxAge": 1,
    "address1": "275 Madison Avenue",
    "industry": "Biotechnology",
    "address2": "7th Floor",
    "previousClose": 0.25,
    "regularMarketOpen": 0.2495,
    "twoHundredDayAverage": 0.23542647,
    "trailingAnnualDividendYield": null,
    "payoutRatio": 0,
    "volume24Hr": null,
    "regularMarketDayHigh": 0.259,
    "navPrice": null,
    "averageDailyVolume10Day": 2983485,
    "totalAssets": null,
    "regularMarketPreviousClose": 0.25,
    "fiftyDayAverage": 0.24861765,
    "trailingAnnualDividendRate": null,
    "open": 0.2495,
    "averageVolume10days": 2983485,
    "expireDate": null,
    "yield": null,
    "algorithm": null,
    "dividendRate": null,
    "exDividendDate": null,
    "beta": 2.167844,
    "circulatingSupply": null,
    "startDate": null,
    "regularMarketDayLow": 0.2446,
    "priceHint": 4,
    "currency": "USD",
    "regularMarketVolume": 1492392,
    "lastMarket": null,
    "maxSupply": null,
    "openInterest": null,
    "marketCap": 41010548,
    "volumeAllCurrencies": null,
    "strikePrice": null,
    "averageVolume": 2822678,
    "priceToSalesTrailing12Months": null,
    "dayLow": 0.2446,
    "ask": 0.259,
    "ytdReturn": null,
    "askSize": 1200,
    "volume": 1492392,
    "fiftyTwoWeekHigh": 0.624,
    "forwardPE": -1.3833333,
    "fromCurrency": null,
    "fiveYearAvgDividendYield": null,
    "fiftyTwoWeekLow": 0.19,
    "bid": 0,
    "tradeable": true,
    "dividendYield": null,
    "bidSize": 1100,
    "dayHigh": 0.259,
    "exchange": "ASE",
    "shortName": "Actinium Pharmaceuticals, Inc. ",
    "longName": "Actinium Pharmaceuticals, Inc.",
    "exchangeTimezoneName": "America/New_York",
    "exchangeTimezoneShortName": "EST",
    "isEsgPopulated": false,
    "gmtOffSetMilliseconds": "-18000000",
    "quoteType": "EQUITY",
    "symbol": "ATNM",
    "messageBoardId": "finmb_7845787",
    "market": "us_market",
    "annualHoldingsTurnover": null,
    "enterpriseToRevenue": null,
    "beta3Year": null,
    "profitMargins": 0,
    "enterpriseToEbitda": -1.262,
    "52WeekChange": -0.5762712,
    "morningStarRiskRating": null,
    "forwardEps": -0.18,
    "revenueQuarterlyGrowth": null,
    "sharesOutstanding": 164700992,
    "fundInceptionDate": null,
    "annualReportExpenseRatio": null,
    "bookValue": 0.06,
    "sharesShort": 2118130,
    "sharesPercentSharesOut": 0.0128999995,
    "fundFamily": null,
    "lastFiscalYearEnd": 1546214400,
    "heldPercentInstitutions": 0.16343,
    "netIncomeToCommon": -23617636,
    "trailingEps": -0.173,
    "lastDividendValue": null,
    "SandP52WeekChange": 0.08368194,
    "priceToBook": 4.15,
    "heldPercentInsiders": 0.013250001,
    "nextFiscalYearEnd": 1609372800,
    "mostRecentQuarter": 1569801600,
    "shortRatio": 0.85,
    "sharesShortPreviousMonthDate": 1579046400,
    "floatShares": 162576522,
    "enterpriseValue": 29628900,
    "threeYearAverageReturn": null,
    "lastSplitDate": null,
    "lastSplitFactor": null,
    "legalType": null,
    "morningStarOverallRating": null,
    "earningsQuarterlyGrowth": null,
    "dateShortInterest": 1581638400,
    "pegRatio": null,
    "lastCapGain": null,
    "shortPercentOfFloat": 0.0128999995,
    "sharesShortPriorMonth": 2314944,
    "category": null,
    "fiveYearAverageReturn": null,
    "regularMarketPrice": 0.2495,
    "logo_url": "https://logo.clearbit.com/actiniumpharma.com"
}